Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
about
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiencyClinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencyHuman normal immunoglobulin in the treatment of primary immunodeficiency diseases.Management of a pregnant woman with common variable immunodeficiency and previous reactions to intravenous IgG administration.Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's diseaseQuantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).Immunodeficiencies.The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins.Modern management of primary B-cell immunodeficiencies.Safety of L-proline as a stabilizer for immunoglobulin products.Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.A review on guidelines for management and treatment of common variable immunodeficiency.A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients.New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients.Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency diseas
P2860
Q34112793-1E60F171-F2BE-42D7-9F17-CD72B9FDFD82Q34196146-DFD768B3-D6CA-4F1F-BCEF-C0604D4CF4CFQ34627045-6CD6E2B5-C9BE-4669-B09C-EA69AA6CB702Q34733689-40EBAC44-66DE-4246-AB86-FFAEF977357FQ35566525-97D43C86-A719-497B-B443-7FA1E75CF27BQ35905557-525FE48E-EE11-4046-A502-CC8301809A30Q35979722-E461E8BC-963D-40B1-98E6-3735A93ABB43Q36065396-7EFC387A-5E36-4974-99F5-BC3326729FCDQ36074636-B23DA40D-05B4-499F-9A19-0DF27D3A794CQ36113220-BDF1948A-0B24-4D86-823E-3920DAAEB9FEQ36196688-01C8A3AA-9826-4574-A7F8-D489CE688EB0Q36462680-6E065709-F483-4586-A278-45AAC8B4B31FQ36688462-BD1DDF1C-4AED-4886-8689-69A39DD8FC58Q37083959-4F746BD4-0DD5-4A59-83CF-3F88ED9DB364Q37083973-FBB01AE3-9E26-4517-9AFD-AB3EA9F4E5D1Q37542243-4BDF7096-3A20-4401-9835-E7AEE693BF47Q37626121-4D48FBEA-C9BF-4A8F-8868-7E99B2F064CFQ37791323-CD1637B7-E17D-470C-B3F3-37E7E5350E81Q37962045-2BE7A522-47F4-4EDF-B1A6-10C715BE8DF7Q37979844-142B8398-CDCD-4F30-B19C-2C7C63786F45Q38042583-0C0D18B9-7DA6-4C01-B045-44861B09B317Q38111423-9A246440-1051-4C48-B093-9049959A64B0Q38188031-D6A0B45C-6826-4BCB-ACC3-0DE2155935E4Q40045651-98CEDCFF-C28A-4E35-B6AA-E185F419428EQ40165686-D16EC6BD-A57F-41F2-82B5-0405EA2E44B2Q40179168-0D4E91E2-F244-40A8-878B-B0AB03F127A1Q40343724-F3D2236B-E240-4F4B-87BF-C74B715ACA89Q40356366-D77D7387-88E0-4CFF-8647-A50FDB5EFA16Q40596658-EC4218BF-30AC-406A-B2B3-02694872806FQ42183204-4E190B3B-3EDB-45CA-A8B2-5E6BBF91C520Q45012826-486DD63F-5F14-4102-90F8-9AB7283B9447Q45762968-282F8192-FE0A-4765-8AEA-DD1DECFDB4B7Q50556522-F01B73C3-31ED-4799-8EAD-C425D0E64255
P2860
Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Safety and efficacy of Privige ...... th primary immunodeficiencies.
@en
Safety and efficacy of Privige ...... th primary immunodeficiencies.
@nl
type
label
Safety and efficacy of Privige ...... th primary immunodeficiencies.
@en
Safety and efficacy of Privige ...... th primary immunodeficiencies.
@nl
prefLabel
Safety and efficacy of Privige ...... th primary immunodeficiencies.
@en
Safety and efficacy of Privige ...... th primary immunodeficiencies.
@nl
P2093
P1476
Safety and efficacy of Privige ...... th primary immunodeficiencies.
@en
P2093
Christiane Vermylen
IgPro10 in PID study group
Johann Bichler
Joseph A Church
Mark R Stein
Michael Borte
Richard L Wasserman
Robert P Nelson
P2888
P304
P356
10.1007/S10875-008-9231-2
P577
2008-09-24T00:00:00Z